Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat to the treatment of asthma in adults

13-11-2013 Business Wire HealthComments (0)

Boehringer IngelheimPharmaceuticalRespimat

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat to the treatment of asthma in adults aged 18 years and over

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top